Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men

International Journal of Impotence Research

Volumn 20, Issue 2, 2008, Pages 213-217

  Grober, E D ^a   Khera, M ^b   Soni, S D ^b   Espinoza, M G ^b   Lipshultz, L I ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Androgens; Hypogonadism; Testosterone gel; Testosterone replacement therapy

Indexed keywords

TESTOSTERONE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLUSHING; GEL; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOGONADISM; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; SYMPTOM; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ANDROGENS; GELS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; TESTOSTERONE; TREATMENT OUTCOME;

EID: 40649125607     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901618     Document Type: Article

References (14)

1. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 2004; 89: 5920-5926.
2. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762-769.
3. Extent Nature of Testosterone Use (News Release). IMS Health: Fairfield, CN, 2006.
4. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003; 91: 69-74.
5. Bouloux P. Testim 1% testosterone gel for the treatment of male hypogonadism. Clin Ther 2005; 27: 286-298.
6. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 4500-4510.
7. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085-2098.
8. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guidelines. J Clin Endocrinol Metab 2006; 91: 1995-2010; http://www.endo-society.org/publications/guidelines/ final/upload/AndrogensMenGuideline053006.pdf.
9. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-1242.
10. SPSS Statistical Software for Windows, Version 14 2007, www.spss.com.
11. Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. J Sex Med 2005; 2: 213-226.
12. Steidle C, Witt MA, Matrisciano J, Block JE. Sexual functioning and satisfaction in nonresponders to testosterone gel: potential effectiveness of retreatment in hypogonadal males. Clin Cornerstone 2005; 7(Suppl 4): S20-S25.
13. Schrader S, Mills A, Scheperle M, Block JE. Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males. Clin Cornerstone 2005; 7(Suppl 4): S26-S31.
14. Marbury T, Hamill E, Bachand R, Sebree T, Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, testim, compared to AndroGel. Biopharm Drug Dispos 2003; 24: 115-120.